Exchange: NYSE·Updated 03:29 PM EDT
News
all
press releases
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Zacks
More News
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Zacks
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Zacks
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
SUPN vs. TEVA: Which Stock Is the Better Value Option?
Zacks
Why Teva Pharmaceutical Stock Surged This Week
Key PointsTeva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations...
Nasdaq News: Markets
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Zacks
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Teva Pharmaceutical Industries Q2 26 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Teva Pharmaceutical Industries (TEVA) will host a conference call at 8:00 AM ET on July 29, 2026, to discuss Q2 26 earnings results...
Nasdaq News: Markets
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Zacks
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Zacks

Advertisement|Remove ads.